| 13:00 – 14:30 | Panel I: MS Biomarkers Revisited: Imaging and fluid biomarkers and beyond in the era of new diagnostic criteria Chairs: Murat Terzi, M. Ufuk Aluçlu |
||
| Panelists: Özlem Ethemoğlu, Atay Vural, Bilgin Öztürk, Sedat Şen, Mehmet Fatih Yetkin |
|||
| 14:30 – 15:15 | Satellite Symposium- Abdi İbrahim MS'te Dimetil Fumarat ve Teriflunomid tedavileri ve Engellilik Chair: Hüsnü Efendi |
||
| MS Tedavisinde Dimetil Fumarat ve Teriflunomid tedavileri Serkan Demir |
|||
| Dimetil Fumarat ve Teriflunomid tedavilerinde Engellilik Verileri Mehmet Fatih Yetkin |
|||
| 15:15 - 15:30 | Break  |
||
| 15:30 – 17:00 | Panel II: Managing MS: Current Treatment Options and Clinical Approaches Chairs: Ömer Faruk Turan, Egemen İdiman |
||
| Panelists: Kadriye Ağan, Esra Gürsoy, Alev Leventoğlu, Semra Mungan, Cihat Uzunköprü, Destan Bünül |
|||
| 17:00-17:45 | Satellite Symposium- Sanovel Chairs: Ayşe Altıntaş, Özlem Ethemoğlu |
||
| 17:00-17:45 | Vakalarla Teriflunomid, Dimetil Fumarat Etkinlik ve Güvenlik Verileri Şeyda Figül Gökçe, Rabia Gökçen Gözübatık Çelik |
||
| 17:45-18:00 | Break |
||
| 18:00-19:00 | Panel III: Young Investigators & European Charcot Foundation Fellowship Community Special Session Chairs: Meral Seferoğlu, Rabia Koç |
||
| 18:00 – 18:05 | Welcome & Introduction Meral Seferoğlu, Rabia Koç |
||
| 18:05 – 18:20 | The Role of ECF with Young Researchers in MS Marjan Steppe |
||
| 18:20– 18:35 | Leadership & Innovation in MS Research: A Youth-Driven Approach Sara Samadzadeh (Virtual) |
||
| 18:35 – 18:50 | Being an MS Master’s Student: Academic and Clinical Reflections Abdülkadir Tunç |
||
| 18:50 – 19:00 | Panel Discussion / Q&A | ||
| 19:00-20:00 | Panel IV: Rehabilitation in MS Chairs: Aysun Ünal, Gürdal Orhan |
||
| Panelist: Cognitive Rehabilitation: Serkan Özakbaş |
|||
| Panelist: Physical Rehabilitation: Mesrure Köseoğlu |
|||
| Panelist: Artificial Intelligence & Brain-Computer Interface: Tuncay Gündüz |
|||
| 20:00 – 20: 20 | Rational Drug Use Session Chair: Tahir Kurtuluş Yoldaş |
||
| 20:20-21:00 | Break & Buffet Dinner on site | ||
| 21:00-23:00 | Panel V: Diagnosing MS and Related Diseases – A Special Evening Event Chair: Sabahattin Saip |
||
| Panelists: Münife Neyal, Özgül Ekmekçi, Sıla Usar, Burcu Altunrende, Haluk Gümüş Case Presentations: Gökçen Gözübatık Çelik, Bedriye Karaman, Duygu Arslan Mehdiyev, İpek Güngör Doğan, Pınar Acar Özen, Ali Özhan Sıvacı |
|||
| 08:00-09:00 | Poster Sessions | ||
| Station 1 Chairs: Melih Tütüncü, Tuncay Gündüz |
|||
| Station 2 Chairs: Aylin Akçalı, Yusuf Tamam |
|||
| Station 3 Chairs: Dürdane Aksoy, Serkan Demir |
|||
| Station 4 Chairs: İlknur Aydın Cantürk, Münire Kılınç |
|||
| Station 5 Chairs: Sedat Şen, Haluk Gümüş |
|||
| 09:00-09:15 | OFFICIAL OPENING & Presentation of the Istanbul MS days awards Chairs: Rana Karabudak, Husnu Efendi, Orhun H. Kantarci, Aksel Siva |
||
| 09:00-09:15 | Opening address and a quick overview of the 10 years of Istanbul MS days Aksel Siva, Rana Karabudak, Orhun H. Kantarci, Husnu Efendi & Jack P. Antel |
||
| 09:15-09:30 | Welcome address 1: The 45 years of MS in 15 minutes Aksel Siva |
||
| 09:30-09:45 | Welcome address 2: Rumi: Between the absolutes of doing it wrong and right Orhun H. Kantarci |
||
| 09:45-10:00 | Presentation of the Istanbul MS days award Aksel Siva, Rana Karabudak, Orhun H. Kantarci, Husnu Efendi |
||
| 10:00-10:30 | Istanbul MS Days: Learning from our mistakes in defining diseases Brain G. Weinshenker |
||
| 10:30-10:45 | Break |
||
| 10:45-12:30 | SESSION-1: Learning from mistakes in science Discussants & Chairs: Frauke Zipp, Riadh Gouider, Cavit Boz |
||
| 10:45-11:00 | Introduction to the session: "Opportunities lost by dismissing or trivializing negative findings in MS research?" Frauke Zipp |
||
| 11:00-11:20 | Learning from Mistakes Janet Hafler |
||
| 11:20-11:40 | Mistakes in the society Boris Zalc |
||
| 11:40-12:00 | Pitfalls of genomic “big-data” Philip L. De Jager |
||
| 12:00-12:30 | Q & A, Discussion | ||
| 12:30-13:30 | Lunch & In-Lunch Satellite Symposium - Farmanova Chair: Aksel Siva |
||
| A New Era of B Cell Therapies: Ofatumumab Celia Oreja-Guevara (Virtual) |
|||
| 13:30-15:00 | SESSION-2: Microglia in MS Discussants & Chairs:Jack P. Antel, Samia Khoury, Erdem Tüzün |
||
| 13:30-13:45 | Introduction to the session - The old friend or new foe: why did we ignore microglia all these years? Jack P. Antel |
||
| 13:45-14:05 | Dynamic and changing roles of microglia in MS Bruce Trapp (Virtual) |
||
| 14:05-14:25 | More questions than answers from BTK inhibitor research in MS Amit Bar-Or |
||
| 14:25-14:45 | Molecular imaging is the answer - Why are you afraid of PET? Laura Airas |
||
| 14:45-15:15 | Q & A, Discussion | ||
| 15:15-15:30 | Break |
||
| 15:30-17:30 | SESSION-3: Modeling MS in the future Discussants & Chairs:Tanja Kuhlmann, Husnu Efendi, Magd Zakaria |
||
| 15:30-15:45 | Introduction to the session: Rethinking Models of MS: Bridging the Gaps Between Pathology, Prediction, and Progress Tanja Kuhlmann |
||
| 15:45-16:05 | Modeling MS pathology: Going beyond EAE Hans Lassmann |
||
| 16:05-16:25 | Modeling the future of MS research: clinical clues that help or mislead Andrew Chan |
||
| 16:25-16:45 | Modeling the future of MS research: MRI clues that help or mislead
Nicola De Stefano |
||
| 16:45-17:15 | Q & A, Discussion | ||
| 17:15-17:30 | Break |
||
| 17:30-19:15 | SESSION-4: Impact of hormones in neuroimmunology Discussants & Chairs: Sandra Vukusic, Ayşe Altıntaş, Gülşen Akman Demir |
||
| 17:30-17:45 | Introduction to the session: Sex Matters in MS: Potential therapeutic inertia affecting treatment in women with MS compared to men Sandra Vukusic |
||
| 17:45-18:05 | What might have been missed by not running sex-specific clinical trials in MS? Kerstin Hellwig |
||
| 18:05-18:25 | Impact of sex hormone switches in neuroimmunology – MS and beyond Burcu Zeydan |
||
| 18:25-18:45 | Impact of sex hormones on animal models of MS Manu Rangachari |
||
| 18:45-19:15 | Q & A, Discussion | ||
| 19:30 | Opening Reception | ||
| 08:00-09:00 | Oral Abstract Presentations | ||
| Hall A - English Abstracts Chairs: Ayşe Sağduyu Kocaman, Cihat Uzunköprü |
|||
| 1.
THE ROLE OF SEX AND MENOPAUSE ON CERVICAL SPINAL CORD ATROPHY IN MS 2. RELAPSİNG REMITTING MULTIPL SKLEROZ’DA HASTALIK SÜRESİNDEN BAĞIMSIZ KOGNİTİF ETKİLENİM VE YAPISAL KORELATLARI - ÖN ÇALIŞMA 3. ANTI-TNF-ALPHA ASSOCIATED CENTRAL NERVOUS SYSTEM DEMYELINATION. DRUG-INDUCED DEMYELİNATİON OR MULTIPLE SCLEROSIS TRIGGER? A CASE SERIES 4. RISK OF CANCER IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH OCRELIZUMAB: THE NATIONAL TREATMENT REGISTRY DATA |
|||
| Hall B Chairs: Belgin Koçer, Mesude Tütüncü |
|||
| 1.
ROLE OF PLACENTAL EXOSOMES IN IMMUNOPATHOLOGY OF NEUROMYELITIS OPTICA SPECTRUM DISORDERS 2. HLA VARIANTS AND DISEASE-MODIFYING THERAPIES IN MULTIPLE SCLEROSIS 3. OPTİK SİNİR TUTULUMUNUN DIS’E DAHİL EDİLMESİ VE MS TANISINDAKİ ETKİLERİ: TEK MERKEZ DENEYİMİ 4. ABSTRACT TITLE: ASSOCIATION OF LESION BURDEN AND LOCATION WITH FATIGUE AND NEUROPATHIC PAIN IN MULTIPLE SCLEROSIS |
|||
| Hall C Chairs: Bilge Piri Çınar, Recai Türkoğlu |
|||
| 1.
RETINAL MICROVASCULARIZATION AND COGNITION IN MULTIPLE SCLEROSIS: AN OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY STUDY 2. MYELİN OLİGODENTROSİT GLİKOPROTEİN ANTİKOR-İLİŞKİLİ HASTALIK (MOGAD): KLİNİK VE RADYOLOJİK ÖZELLİKLER 3. OCRELIZUMAB: DOES IT`S MARVEL DECLINE BY AGE? 4. MULTİPL SKLEROZ HASTALARINDA HASTALIĞIN YÜRÜME FONKSİYONLARI ÜZERİNDEKİ ETKİSİNİN TİNETTİ DENGE VE YÜRÜME TESTİ İLE DEĞERLENDİRİLMESİ 5. PEDİATRİK MULTİPL SKLEROZ HASTALARINDA NÖROBİLİŞSEL İŞLEVLER VE RUHSAL DURUM PEDİATRİK MULTİPL SKLEROZ HASTALARINDA NÖROBİLİŞSEL İŞLEVLER VE RUHSAL DURUM DEĞERLENDİRMESİ 6. PEDİATRİK BAŞLANGIÇLI DEMİYELİNİZAN HASTALIK TANILI HASTALARIN ERİŞKİN NÖROLOJİ POLİKLİNİĞİNE DERVİNDEN SONRA İZLEMİNİN DEĞERLENDİRMESİ |
|||
| Hall D Chairs: Belgin Petek Balcı, Yılmaz İnanç |
|||
| 1.
MULTİPL SKLEROZ’DA DİMETİL FUMARAT TEDAVİSİNİN SİSTEMİK İNFLAMATUAR YANIT İNDEKSİNE ETKİSİNİN İNCELENMESİ 2. IN PATIENTS WITH MULTIPLE SCLEROSIS DIAGNOSIS CHITINASE 3 LIKE 1 AND CHITINASE 3 LIKE 2 LEVELS 3. PEDİATRİK MULTİPLE SKLEROZ HASTALARINDA İNTESTİNAL MİKROBİYOTA DEĞİŞİKLİKLERİ 4. EVALUATION OF THE RELATIONSHIP OF ALLOPREGNANOLONE LEVELS WİTH OXIDATIVE STRESS INDEX AND DISEASE COURSE CHARACTERISTICS IN PEOPLE WITH MULTIPLE SCLEROSIS 5. KLADRİBİN TEDAVİSİ ALAN MS HASTALARINDA KLİNİK SEYİR, YAN ETKİLER VE HASTA MEMNUNİYETİ: GERÇEK YAŞAM VERİLERİ 6. RELAPSING-REMITTING MULTIPLE SKLEROZ HASTALIĞINDA OCRELIZUMAB’IN BIRINCI BASAMAKTA KULLANIMI ILE YARATTIĞI MEDIKAL DEĞER |
|||
| Hall E Chairs: Aslı Köşkderelioğlu, Levent Sinan Bir |
|||
| 1.
IS YOUR MULTIPLE SCLEROSIS PATIENT’S PAIN JUST NEUROPATHIC OR COULD IT BE FIBROMYALGIC?
2. MULTİPLE SKLEROZLU BİREYLERDE BOYUN AĞRISININ SERVİKAL PROPRİYOSEPSİYON, ÜST EKSTREMİTE FONKSİYONELLİĞİ VE DENGE İLE İLİŞKİSİNİN İNCELENMESİ 3. MULTİPL SKLEROZ HASTALARINDA OPTİK SİNİRE AİT DİFÜZYON TENSOR GÖRÜNTÜLEME BULGULARI 4. MULTİPLE SKLEROZ’DA OKRELİZUMAB TEDAVİSİ: TEK MERKEZLİ BİR KOHORT ÇALIŞMASI 5. MULTİPL SKLEROZLU BİREYLERDE STİGMA VE YAŞAM KALİTESİ İLE ÖZÜRLÜLÜK ÜZERİNDEKİ ETKİLERİ 6. CLADRIBINE AS AN EXIT THERAPY IN OLDER PATIENTS WITH MULTIPLE SCLEROSIS: THE CLEXIT STUDY |
|||
| 09:05-11:00 | SESSION - 5: Myelin gets sick early in MS Discussants & Chairs: Catherine Lubetzki, Aslı Tuncer, Murat Kürtüncü |
||
| 09:05-09:20 | Introduction to the session- Myelin is not the only actor in MS Catherine Lubetzki |
||
| 09:20-09:40 | More questions than answers in remyelination trials in MS Peter Calabresi (virtual) |
||
| 09:40-10:00 | Interactions between astrocytes and oligodendroglia in MS Daniel Reich |
||
| 10:00-10:20 | PET as a single quantitative remyelination marker for clinical trials Bruno Stankoff |
||
| 10:20-10:50 | Q & A, Discussion | ||
| 10:50-11:05 | Break |
||
| 11:05-12:50 | SESSION - 6: Simplifying the clinical phenotype definitions of MS Discussants & Chairs: Andrew J. Solomon, Rana Karabudak, Refik Pul |
||
| 11:05-11:20 | Introduction to the session: Has the new diagnostic criteria increased or decreased the risk of misdiagnosis in MS globally? Andrew J. Solomon |
||
| 11:20-11:40 | Single agnostic definition of MS – the imaging-clinical continuum Orhun Kantarci |
||
| 11:40-12:00 | Extremes of MS - Aggressive versus benign Ellen Mowry |
||
| 12:00-12:20 | Separation of targets for differing trial endpoints – PIRA vs. RAW Daniel Ontaneda |
||
| 12:20-12:50 | Q & A, Discussion | ||
| 12:50-13:50 | Lunch & In-Lunch Satellite Symposium - Roche Chair: Aslı Tuncer |
||
| Timing of Ocrelizumab in MS: Clinical Impact and Efficacy of On Time Initiation Speaker: Angela Vidal Jordana |
|||
| 13:50-15:30 | SESSION-7: Defining MS phenotypes by biomarkers Discussants & Chairs: Eric Thouvenot, Jorge Correale, Ugur Uygunoglu |
||
| 13:50-14:05 | Introduction to the session: From Missteps to Milestones: Rethinking Biomarkers in MS Phenotyping Eric Thouvenot |
||
| 14:05-14:25 | Biomarkers of pre-symptomatic disease in MS – lessons from RIS Christine Lebrun-Frenay |
||
| 14:25-14:45 | Pre- and post-symptomatic immunophenotypes of MS Heinz Wiendl (virtual) |
||
| 14:45-15:05 | Should AI care for our definitions of MS phenotypes? Vilas Menon |
||
| 15:05-15:35 | Q & A, Discussion | ||
| 15:35-15:50 | Break |
||
| 15:50-17:35 | SESSION-8: Risk factor mitigation in MS Discussants & Chairs: Nikolaos Grigoriadis, Eda Tahir Turanlı, Yeşim Beckman |
||
| 15:50-16:05 | Introduction to the session: Mitigation Starts with Recognition: The Cost Of not addressing risk of MS Nikolaos Grigoriadis |
||
| 16:05-16:25 | Lessons from our mistakes in epidemiology of MS Alberto Ascherio |
||
| 16:25-16:45 | Is the gut the new solution for the brain? David Hafler |
||
| 16:45-17:05 | EBV vaccination or microbiome transfer – which is the better path forward for MS prevention? Thomas Berger |
||
| 17:05-17:35 | Q & A, Discussion | ||
| 17:35-17:50 | Break |
||
| 17:50-19:35 | SESSION - 9: Larger than life clinical trials in MS Discussants & Chairs: Ludwig Kappos, Hans-Peter Hartung, Melih Tutuncu |
||
| 17:50-18:05 | Introduction to the session: Decades of Experience in MS Therapeutic Trials: Key Lessons Learned Ludwig Kappos |
||
| 18:05-18:25 | Give me the ideal clinical trial in MS - what is amiss in the past ones? Xavier Montalban (virtual) |
||
| 18:25-18:45 | Real value of harmonization of imaging for clinical trials Maria Pia Sormani (virtual) |
||
| 18:45-19:05 | Loosing specificity while looking for commonality and sensitivity in MS trials Jiwon Oh |
||
| 19:05-19:35 | Q & A, Discussion | ||
| 20:00 | Leave for dinner | ||
| 08:00-08:45 | Morning Satellite Symposium - Alexion Targeting the Source: Complement Blockade in NMOSD Chair: Ayşe Altıntaş |
||
| 08:00-08:10 | Pathogenesis of NMOSD: Central Role of AQP4 Antibodies and the Complement System Ayşe Altıntaş |
||
| 08:10-08:20 | Targeted Therapy Through Complement Inhibition Melih Tütüncü |
||
| 08:20-08:30 | Clinical Efficacy, Safety, and Real-World Data of Eculizumab in NMOSD Jin Nakahara |
||
| 08:30-08:45 | Q&A All Panelists |
||
| 08:45-10:15 | SESSION - 10: Don’t ignore cognition in MS Discussants & Chairs: Anat Achiron, Najib Kissani, Serkan Demir |
||
| 08:45-08:55 | Introduction to the session: We protected the brain but lost the mind in MS! Anat Achiron |
||
| 08:55-09:15 | Complex imaging signatures of cognitive decline in MS Korhan Buyukturkoglu |
||
| 09:15-09:35 | Impact of ethnicity on cognition in MS Nabeela Nathoo |
||
| 09:35-09:55 | Roadblocks to treating cognition sufficiently in MS Claire Riley (virtual) |
||
| 09:55-10:15 | Q & A, Discussion | ||
| 10:15-10:30 | Break |
||
| 10:30-12:00 | SESSION - 11: Imaging developments in MS Discussants & Chairs: Nur Yüceyar, Mohammad Ali Sahraian, Serhat Okar |
||
| 10:30-10:40 | Introduction to the session: Rethinking what we are measuring by imaging by MRI and PET in MS Serhat Okar |
||
| 10:40-11:00 | What is going on in the deep gray matter in MS Christina Azevedo |
||
| 11:00-11:20 | What is going on in the normal appearing white matter in MS Cristina Granziera |
||
| 11:20-12:00 | Q & A, Discussion | ||
| 12:00-13:00 | Lunch & In-Lunch Satellite Symposium - Merck Chair: Rana Karabudak |
||
| Mavenclad in MS Treatment Refik Pul |
|||
| 13:00-14:45 | SESSION-12: Propensity for autoimmunity Discussants & Chairs: Hayrettin Tumani, Dicle Güç |
||
| 13:00-13:15 | Introduction to the session: Common Risk Pathways in Autoimmunity Hayrettin Tumani |
||
| 13:15-13:35 | A bioinformatics architecture of susceptibility to autoimmunity Mika Gustaffson |
||
| 13:35-13:55 | Role of TCR as key to autoimmunity Batu Erman |
||
| 13:55-14:15 | Tregs in MS
David Hafler |
||
| 14:15-14:45 | Q & A, Discussion | ||
| 14:45-15:00 | Break |
||
| 15:00-16:45 | SESSION-13: Don’t ignore the children Discussants & Chairs: Jacqueline Palace, Sema Saltık |
||
| 15:00-15:15 | Introduction to the session: From Childhood to Adulthood: Unraveling CNS Autoimmunity Across Ages Jacqueline Palace |
||
| 15:15-15:35 | Why are CNS inflammatory disorders more aggressive in children Naila Makhani (virtual) |
||
| 15:35-15:55 | Autoimmune leukoencephalopathies in children Silvia Tenembaum |
||
| 15:55-16:15 | Differences in children’s brain imaging compared to adults in MS Matilde Inglese (virtual) |
||
| 16:15-16:45 | Q & A, Discussion | ||
| 16:45-17:00 | Break |
||
| 17:00-19:00 | SESSION - 14: Advances in MOG and NMO autoimmunity Discussants & Chairs: Kazuo Fujihara, Nasrin Asgari, Paulus Rommer |
||
| 17:00-17:15 | Introduction to the session: Lessons From the Era of NMOSD as Distinct From MS at the Turn of the Millennium Kazuo Fujihara |
||
| 17:15-17:35 | The Many Faces of MOG autoimmunity Romain Marignier |
||
| 17:35-17:55 | Mechanism of action of MOG antibodies Orhan Aktaş |
||
| 17:55-18:15 | What does MOG autoimmunity teach us about post-inflammatory CNS diseases? Axel Petzold |
||
| 18:15-18:35 | The strange case of MOG- Why does it not progress like MS? Eoin Flanagan |
||
| 18:35-19:00 | Q & A, Discussion | ||
| 19:00-20:00 | SESSION-15: Summary of the meeting Chairs: Serhan Sevim, Nilüfer Kale İçen Speakers: Serkan Özben, Mesude Tütüncü, Bilge Piri Çınar, Gülgün Uncu, Ahmet Kasım Kılıç |
||
| 20:15 | Departure for Farewell Dinner | ||